Welcome to our dedicated page for Leidos Holdings news (Ticker: LDOS), a resource for investors and traders seeking the latest updates and insights on Leidos Holdings stock.
Leidos Holdings, Inc. (NYSE: LDOS) is a leading science and technology company that provides services and solutions in defense, intelligence, civil, and health markets. Headquartered in Reston, Virginia, Leidos leverages the expertise of its 47,000 employees to tackle some of the world's most pressing challenges. The company is divided into several segments, each catering to specific industries:
- National Security and Digital: Focuses on cyber, logistics, security operations, and digital transformation for defense and intelligence customers.
- Health & Civil: Delivers public health solutions, care coordination, and environmental sciences services.
- Commercial & International: Covers security enterprise solutions, commercial energy offerings, and international business.
- Defense Systems: Develops advanced space, aerial, surface, and subsurface defense systems.
Leidos reported revenues of approximately $15.4 billion for the fiscal year ending December 29, 2023. The company’s recent projects include:
- Development of C2IMERA: An advanced command and control tool for the U.S. Air Force.
- MHS GENESIS Deployment: A federal electronic health record system implemented across all Department of Defense garrison facilities.
- Mayhem Hypersonic System: Advancing air-breathing hypersonic technologies through a collaborative national team effort.
Financially, Leidos had a strong 2023 with revenues up by 7%, achieving a record net income margin of 7.1% in the first quarter of 2024. The company remains committed to innovation, operational efficiency, and addressing emerging threats in national security and health.
Leidos (NYSE: LDOS) received the 2021 Public Sector SI Partner of the Year Award from Splunk for outstanding performance, especially in creating telehealth dashboards for the U.S. Department of Veterans Affairs during the COVID-19 pandemic. The dashboards supported a ten-fold increase in telehealth usage by analyzing over 72 million daily events, significantly reducing connection errors from 1,000 to under 10 per day. This award reflects Leidos' commitment to innovation and customer success, solidifying its position as a leading Systems Integrator in the public sector.
Leidos (NYSE:LDOS) has been awarded a prime contract by U.S. Customs and Border Protection (CBP) valued at $480 million for the provision of Multi-Energy Portal (MEP) systems. This contract spans a base period of five years, with options extending to ten years. The MEP systems will be integrated in Vista, California, enhancing non-intrusive inspections at U.S. ports. The technology will assist in screening over 22 million containers annually, improving detection of contraband and enhancing operational efficiency for CBP.
Leidos (NYSE:LDOS) has completed the delivery of the Seahawk, an advanced autonomous vessel, to the U.S. Navy. This delivery, part of a $35.5 million contract awarded in December 2017, represents a significant technological advancement in naval operations. Seahawk features a composite trimaran hull and is designed for high availability and long-range operations with minimal human intervention. It enhances capabilities compared to conventional unmanned surface vehicles (USVs). The vessel will be stationed in San Diego, California, augmenting the Navy's maritime surveillance capabilities.
Leidos (NYSE: LDOS) has announced a conference call for May 4, 2021, at 8 a.m. (ET) to reveal its first quarter financial results for the period ending April 2, 2021. The earnings press release will be issued prior to the call. Investors can access the call via a live audio broadcast or a telephone line: 877-869-3847 (toll-free U.S.) and +1-201-689-8261 (International). A replay will be available starting at 11:30 a.m. (ET) on the same day until May 11, 2021.
Leidos (NYSE: LDOS) has partnered with the Baltimore Ravens for their second year to address the opioid epidemic through the "Tackling Opioid Addiction" campaign. This initiative will provide support to Oxford House, a nonprofit offering recovery residences for individuals battling substance use disorders. Leidos and the Ravens will donate to assist new residents on their recovery journey, highlighting the rising need for such support during the COVID-19 pandemic. Leidos reported approximately $12.30 billion in revenues for FY 2021.
Leidos (NYSE: LDOS) has secured a prime contract valued at $149.2 million from the Naval Undersea Warfare Center to provide engineering, technical, and management services for the Naval Array Technical Support Center. This contract, focused on undersea warfare solutions, is indefinite delivery/indefinite quantity with work primarily in Newport, Rhode Island. Leidos will enhance support for the Navy's towed array assets, demonstrating its commitment to innovative technologies and maintaining a competitive edge in undersea operations.
Leidos (NYSE: LDOS) will participate in the Bank of America Global Industrials Conference 2021 on March 17, 2021, at 3:00 p.m. ET. Jim Reagan, Chief Financial Officer, will engage in a fireside chat during the event. An audio webcast of the conference can be accessed via the Leidos Investor Relations website, with a replay available until September 14, 2021. Leidos, a leading science and technology company, reported annual revenues of approximately $12.30 billion for the fiscal year ending January 1, 2021.
Leidos (NYSE: LDOS), a leading technology and engineering company, will join the J.P. Morgan 2021 Virtual Industrials Conference. CEO Roger Krone is set to engage in a 'fireside chat' on March 16, 2021, at 3:40 p.m. ET. Investors can access a live audio webcast on the Leidos Investor Relations website, with a replay available for 30 days post-event. For the fiscal year ended January 1, 2021, Leidos reported revenues of approximately $12.30 billion. For more details, visit www.Leidos.com.
Leidos (LDOS) has secured a $22 million project agreement from the Defense Threat Reduction Agency (DTRA) to conduct clinical studies on COVID-19 therapeutics. This cost-plus-fixed-fee agreement spans 24 months and reinforces Leidos' commitment to combat the pandemic. The company will utilize a new clinical trial prototype for real-time data collection, enabling simultaneous studies of drug combinations to enhance treatment outcomes and military readiness. Collaboration with Personal Health Insights, Syneos Health, and SCOPE International aims to optimize trial efficiency and patient safety monitoring.
FAQ
What is the current stock price of Leidos Holdings (LDOS)?
What is the market cap of Leidos Holdings (LDOS)?
What does Leidos Holdings, Inc. do?
Where is Leidos Holdings, Inc. headquartered?
How many employees does Leidos have?
What are the main business segments of Leidos?
What were Leidos' revenues for the fiscal year 2023?
What is C2IMERA?
What is MHS GENESIS?
What recent project has Leidos completed for the Air Force Research Lab?
What are the recent financial highlights for Leidos?
How does Leidos contribute to national security?
